In a report released on September 8, Brian Skorney from Robert W. Baird maintained a Hold rating on Reata Pharmaceuticals (RETA – Research Report), with a price target of $27.00. The company’s shares closed last Friday at $26.50.
According to TipRanks, Skorney is an analyst with an average return of -4.1% and a 46.29% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Biogen, and Neurocrine.
Reata Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $40.50.
See the top stocks recommended by analysts >>
The company has a one-year high of $114.80 and a one-year low of $18.47. Currently, Reata Pharmaceuticals has an average volume of 747.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. Südhof, Jonathan M. Graff and J. Warren Huff on September 1, 2002 and is headquartered in Irving, TX.
Read More on RETA:
- Energy Transfer (ET) Receives a Buy from Mizuho Securities
- Robert W. Baird Keeps Their Hold Rating on Immunovant (IMVT)
- Eiger Biopharmaceuticals (EIGR) Gets a Buy from Robert W. Baird
- Coupa Software (COUP) Receives a Hold from Mizuho Securities
- Jack Henry & Associates (JKHY) Gets a Hold from Robert W. Baird